Результаты поиска

Second autologous hematopoietic stem cell transplantation in multiple myeloma.

BACKGROUND: High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. Second ASCT2 is a salvage option for selected patients with durable remission after ASCT1. Reports from the Asia-Pacific region are limited. METHODS: This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. Demographics, treatment characteristics, toxicity, engraftment, and outcomes were analyzed. All patients underwent fresh stem cell mobilization with granulocyte colony-stimulating facto…

Все ли факторы риска равны в множестве миеломы?

Данные отсутствуют.

Совпадение в полном тексте источника
… Are all risk factors created equal in multiple myeloma? by Sina A. Beer and Martin F. Kaiser Received: September 2, 2026. Accepted: September 9, 2026. Citation: Sina A. Beer and Martin F. Kaiser. Are all risk factors created equal in multiple myeloma? … A gene expression signature for high- risk multiple myeloma. Leukemia. 2012;26(11):2406-2413. 6. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. 7. Skerget S, Penaherrera D, Chari A, et al. …

Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma.

Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib. Conversely, inhibition of VLCFA degradation via suppression of peroxisomal acyl-CoA oxidase 1 (ACOX1) increased the cytotoxicity of bortezomib, its next-generation analog, carfilzomib, and the immunomodulatory ag…

Predicting survival of persons with newly-diagnosed multiple myeloma.

BACKGROUND: Predicting survival in newly diagnosed multiple myeloma (NDMM) patients accurately remains challenging. Although mSMART3.0 is widely used it has not been rigorously tested for prediction accuracy. METHODS: We analysed clinical and laboratory variables in 1,008 NDMM patients, randomly split into a training set (n = 704) and a validation set (n = 304). Univariable and multivariable Cox regression analyses identified independent prognostic factors, forming a baseline survival model. For patients with available mSMART3.0 data, we integrated it with the baseline nomogram to enhance pred…

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application.

Multiple myeloma (MM), characterised by the clonal proliferation of plasma cells in the bone marrow, is the second most common haematological malignancy worldwide. Although there is now an impressive artillery of therapeutics to tackle this condition, resistance remains a prevalent issue. The bone marrow microenvironment performs a crucial role in supporting MM pathogenesis and promoting the development of therapeutic resistance. Extracellular vesicles (EVs), small vesicles that carry bioactive molecules, are a key component of cell-to-cell communication within the bone marrow microenvironment…

Toxicity of CAR T-Cell Therapy for Multiple Myeloma.

BackgroundIdecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T cell therapies targeting B-cell maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for the treatment of relapsed and refractory multiple myeloma (RRMM).SummaryThese therapies offer unprecedented responses in RRMM but present new challenges including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, cytopenias, infections, and hypogammaglobul…

Progress of immune senescence in multiple myeloma treatment resistance.

Multiple myeloma has become the second most common hematologic malignancy threatening human health with the increasing incidence in the population, and the emergence of drug resistance in its treatment has become a problem that needs to be solved urgently. Recent studies have shown that the immune system is closely related to the development of multiple myeloma, and immune senescence plays an extremely critical role in MM treatment resistance. In this paper, we review the connection between immune senescence and the development of MM and its possible role in the drug resistance of MM treatment…

Агрессивная экстрамеуллярная миелома, представляющая собой маленькое препятствование.

De novo extramedullary multieloma (EMM) — редкая подмножество миеломы (MM), определяемая наличием клональных плазменных клеток (PC) за пределами костного мозга. Она связана с рефракторными заболеваниями и неблагоприятными последствиями. Даже в ЭММ плазменные цитомы внутри дуоденума, джеджунум и лилум редко встречаются при меньшем количестве 70 - случаи, о которых сообщается в литературе. Здесь мы представляем особо агрессивный случай ЭММ, который привел к тому, что маленький кишечник стал преградой для внутрисветовой плазмоцитомы во время лечения миэломы. Пациент прошел хирургическую пересечен

Совпадение в аннотации оригинала
De novo extramedullary multiple myeloma (EMM) is a rare subset of multiple myeloma (MM) defined by the presence of clonal plasma cells (PC) outside of the bone marrow. It is associated with refractory disease and adverse outcomes. Even in EMM, plasmacytomas within the duodenum, jejunum, and ileum are uncommon, with fewer than 70 cases reported in the literat…

Прогнозирующее воздействие симптомов, сообщенных пациентом в множестве миеломы.

Результаты, о которых сообщается в " AbstractPatient " (PROs), связаны с результатами лечения в множестве миеломы (ММ) при клинических испытаниях. Однако большинство инструментов ПРО занимает много времени, что затрудняет их использование в повседневной практике. Наше учреждение включило в себя "Скриншот с гематологическими симптомами пациента" (HPRSS), a. 3-item - вопросник по усталости, боли и качеству жизни (КОЛ). Основная цель этого исследования заключалась в оценке воздействия этих симптомов на выживаемость без прогрессирования (ПФС) и общее выживание (ОС) в реальной группе паци

Совпадение в аннотации оригинала
AbstractPatient-reported outcomes (PROs) are associated with treatment outcomes in multiple myeloma (MM) in the clinical trial setting. However, most PRO tools are time consuming, which hinders use in routine practice. Our institution incorporated a "Hematology Patient-Reported Symptom Screen" (HPRSS), a 3-item questionnaire for fatigue, pain, and quality of…

Emerging roles of protein arginine methyltransferase in multiple myeloma.

Multiple myeloma (MM) is a cancer of plasma cells characterized by the clonal expansion of abnormal plasma cells in the bone marrow. These malignant cells overcrowd the bone marrow, disrupt normal hematopoiesis, and produce excessive amounts of immunoglobulins, leading to severe clinical manifestations. Despite significant advancements in treatment, relapsed/refractory MM remains incurable. Protein arginine methylation, catalyzed by protein arginine methyltransferases (PRMTs), is a critical post-translational modification involved in regulating various cellular processes. Aberrant expression o…

Предотвращение событий, связанных со скелетом, в новой диагностированной миеломе.

Несмотря на увеличение числа новых методов лечения недавно диагностированной множественной миеломы (НДММ), предотвращение событий, связанных со скелетом (СРП), по-прежнему является сложной задачей. В настоящем обзоре резюмируются механистические причины болезни костей миэломы, данные, подтверждающие использование бисфофонатов и ингибиторов РАНКЛ, а также оптимальное управление предотвращением НОС у пациентов НДММ. Как золедронная кислота (ZA), так и деносумаб являются приемлемыми вариантами обработки с сопоставимыми характеристиками безопасности и эффективности. Однако у пациентов, которые явл…

Impact of Social Vulnerability Index on Multiple Myeloma Mortality.

INTRODUCTION: The incidence of multiple myeloma (MM) in the USA has been increasing over the past decades with persistent demographic disparities. Social determinants of health (SDOH) were found to affect health outcomes among certain diseases. However, there were limited data on the impact of SDOH on the MM mortality rates. Our study aimed to investigate the association between the SDOH and MM mortality rates from 2016 to 2020. METHODS: County-level data from the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index (CDC/ATSDR …